PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis
| العنوان: | PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis |
|---|---|
| المؤلفون: | Ken Herrmann, Maximilian Spanke, Michael Schäfers, Jens Kleesiek, Matthias Weckesser, Katharina Kessel, Katrin Schlack, Manuel Weber, Robert Seifert, Boris Hadaschik, Martin Boegemann, Wolfgang P. Fendler, Kambiz Rahbar |
| المصدر: | European Journal of Nuclear Medicine and Molecular Imaging |
| بيانات النشر: | Springer Science and Business Media LLC, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Male, Oncology, medicine.medical_specialty, PET-CT, Lesion Number, urologic and male genital diseases, Lesion, Heterocyclic Compounds, 1-Ring, Prostate cancer, Positron Emission Tomography Computed Tomography, Internal medicine, PSMA, medicine, Radioligand, Humans, Radiology, Nuclear Medicine and imaging, In patient, Retrospective Studies, Lu-PSMA, Proportional hazards model, business.industry, Dipeptides, General Medicine, mCRPC, Prostate-Specific Antigen, Total tumor volume, medicine.disease, Tumor Burden, Prostatic Neoplasms, Castration-Resistant, Treatment Outcome, Psma pet, Original Article, medicine.symptom, business |
| الوصف: | Introduction [177Lu]Lu-PSMA-617 (Lu-PSMA) radioligand therapy is an emerging treatment option for patients with end-stage prostate cancer. However, response to Lu-PSMA therapy is only achieved in approximately half of patients. It is clinically important to identify patients at risk of poor outcome. Therefore, the aim of this study was to evaluate pretherapeutic PSMA PET derived total tumor volume and related metrics as prognosticators of overall survival in patients receiving Lu-PSMA therapy. Methods A total number of 110 patients form the Departments of Nuclear Medicine Münster and Essen were included in this retrospective analysis. Baseline PSMA PET-CT was available for all patients. Employing a previously published approach, all tumor lesions were semi-automatically delineated in PSMA PET-CT acquisitions. Total lesion number, total tumor volume (PSMA-TV), total lesion uptake (PSMA-TLU = PSMA-TV * SUVmean), and total lesion quotient (PSMA-TLQ = PSMA-TV / SUVmean) were quantified for each patient. Log2 transformation was used for regressions. Results Lesion number, PSMA-TV, and PSMA-TLQ were prognosticators of overall survival (HR = 1.255, p = 0.009; HR = 1.299, p = 0.005; HR = 1.326, p = 0.002). In a stepwise backward Cox regression including lesion number, PSMA-TV, PSA, LDH, and PSMA-TLQ, only the latter two remained independent and statistically significant negative prognosticators of overall survival (HR = 1.632, p = 0.011; HR = 1.239, p = 0.024). PSMA-TLQ and LDH were significant negative prognosticators in multivariate Cox regression in contrast to PSA value. Conclusion PSMA-TV was a statistically significant negative prognosticator of overall survival in patients receiving Lu-PSMA therapy. PSMA-TLQ was an independent and superior prognosticator of overall survival compared with PSMA-TV. |
| تدمد: | 1619-7089 1619-7070 |
| DOI: | 10.1007/s00259-020-05040-1 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da51e8e3cd3bd2992df809a5c4dd51cb https://doi.org/10.1007/s00259-020-05040-1 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....da51e8e3cd3bd2992df809a5c4dd51cb |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 16197089 16197070 |
|---|---|
| DOI: | 10.1007/s00259-020-05040-1 |